Analysis of the pharmaceutical market of drugs used in the pharmacotherapy of bronchial asthma in the Kyrgyz Republic

The article presents the results of the analysis of the pharmaceutical market of drugs used in the pharmacotherapy of bronchial asthma in the Kyrgyz Republic. The materials of the study were the pharmaceutical market of medicines used for the treatment of bronchial asthma in the Kyrgyz Republic, the data of the regulatory authority in the field of circulation of medicines and pharmaceutical organizations. Research results. It was established that in the Kyrgyz Republic the analyzed group of drugs included in the clinical protocol for the treatment of bronchial asthma is represented by 56 trade names. In the nomenclature of drugs for the treatment of bronchial asthma, the leading place belongs to single drugs - 87.5%, the share of combined drugs, respectively, is 12.5%. Of the total number of anti-asthma drugs in the pharmaceutical market, lecotriene receptor antagonists rank first with a share of 46.29%, β2-agonists - 37%, combined glucocorticosteroids - 17.83%, inhaled glucocorticosteroids - 29.62% and glucocorticosteroids for systemic use - 24%, methylxanines - 9.25%, anticholinergics - 7.4%. Conclusion. Drugs for the treatment of bronchial asthma, present on the pharmaceutical market of the Kyrgyz Republic, in general, comply with the recommendations of the experts of the Global Initiative for Asthma (GINA) (Global Initiative for Asthma). All medicines on the pharmaceutical market of the Kyrgyz Republic are represented exclusively by foreign manufacturers, among which Turkey is the leader.